

FF
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission 29

Application Number

10/526,127

Filing Date

28 February 2005

First Named Inventor

Peter Anthony CAMPOCHIARO

Art Unit

To Be Assigned

Examiner Name

To Be Assigned

Attorney Docket Number

116566-002

ENCLOSURES (Check all that apply)

- Fee Transmittal Form
- Fee Attached
- Amendment/Reply
 - After Final
 - Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority Document(s)
- Reply to Missing Parts/ Incomplete Application
 - Reply to Missing Parts under 37 CFR 1.52 or 1.53

- Drawing(s)
- Licensing-related Papers
- Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation
- Change of Correspondence Address
- Terminal Disclaimer
- Request for Refund
- CD, Number of CD(s) _____
- Landscape Table on CD

Remarks

- After Allowance Communication to TC
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Other Enclosure(s) (please Identify below):
 - Stamped Return receipt postcard
 - Copy of 23 March 2006 filing papers (27 pages)

RECEIVED
22-6 JUL 2006
2006

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

*Legal Staff
International Division*

Firm Name	Bell, Boyd & Lloyd PLLC		
Signature	<i>Jeff Howell Reg. No. 46,402 for</i>		
Printed name	Dean H Nakamura		
Date	26 May 2006	Reg. No.	33,981

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Heather Foster

Date 26 May 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Campochiaro et al.
Appl. No.: 10/526,127
Conf. No.: 2577
Filed: 28 February 2005
Title: OCULAR GENE THERAPY
Art Unit: Unassigned
Examiner: Unassigned
Docket No.: 116566-002



Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION TO WITHDRAW NOTIFICATION OF ABANDONMENT

Sir:

In a Communication mailed 17 April 2006, the Office maintained the above-captioned application is abandoned because of allegedly not responding to the Notice of Missing Requirements mailed 23 December 2005.

The Notification of Abandonment is in error as a timely and fully responsive reply to the Notice of Missing Requirements was filed.

Attached hereto is a copy of a stamped Postcard which accompanied the filing, as well as a copy of the fully responsive filing.

Moreover, the period for response along with the appropriate extension fee has not yet lapsed and the opportunity to reply remains open until 23 July 2006.

Hence, in light of the facts stated above and the evidence attached hereto, withdrawal of the Notification of Abandonment and return to pending status are requested respectfully.

It is believed no fee is necessary for the instant petition. However, if the Commissioner finds to the contrary, Deposit Account No. 02-1818 can be debited the appropriate fee for the instant petition and any other fee associated with the instant petition.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY

Dean H. Nakamura


Reg. No. 33,981

P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (202) 955-6851

Dated: 25 May 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/526,127	Peter Anthony campochiaro	116566-002
		INTERNATIONAL APPLICATION NO.
		PCT/EP03/09497
I.A. FILING DATE		PRIORITY DATE
08/27/2003		08/28/2002
CONFIRMATION NO. 2577		
371 ABANDONMENT/TERMINATION LETTER		
 *OC000000018542636*		

Date Mailed: 04/17/2006

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

- Applicant has failed to respond to the notification of MISSING REQUIREMENTS (Form PCT/DO/EO/905), mailed 12/23/2005 within the time period set therein.

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

SHELBY J VIGIL

Telephone: (703) 308-9140 EXT 224

RECEIVED
BELL, BOYD & LLOYD
INTELLECTUAL PROPERTY DOCKET
 PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)

APR 20 2006

ATTY DHN
 DOCKET # 16566-002



APR 3 Rec'd PCT/PTO 27 MAR 2006

In re Patent Application of: Campochiaro et al.

OCULAR GENE THERAPY

Docket No. 116566-053

On the date stamped hereon the U.S. Patent & Trademark Office hereby acknowledges the receipt of the following:

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning A Submission Under 35 U.S.C. 371 (duplicate);
2. Copy of Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US);
3. Petition for Extension of Time (duplicate);
4. Declaration and Power of Attorney (4 pages);
5. Computer-readable form of sequence listing;
6. Sequence Listing Certification;
7. Paper copy of Sequence Listing (8 pages);
8. Check in the amount of \$250.00.

Mailed by First Class Mail by DHN on 23 March 2006

RECEIVED
BELL, BOYD & LLOYD
INTELLECTUAL PROPERTY DOCKET

APR 03 2006

ATTY DHW
BOOKET # 116566-053



D & LLOYD LLC PATENTS & TRADEMARKS ACCOUNT

028265

INVOICE NUMBER	INVOICE DATE	AMOUNT	ACCOUNT CODE	DESCRIPTION
1059	03/23/06	130.00	0116566 00002	Surcharge for furnishing the oath or declaration after the date of commencement of the national stage
1059	03/23/06	120.00	0116566 00002	One month extension of time
Nakamura				

BELL, BOYD & LLOYD LLC
PATENTS & TRADEMARKS ACCOUNT
THREE FIRST NATIONAL PLAZA
ADISON ST. STE 13300 PH. 312-372-1121
CHICAGO, IL 60602

LASALLE BANK, N.A.
CHICAGO, ILLINOIS 60603

250
710

028265

CHECK DATE	CONTROL NUMBER	CHECK AMOUNT
03/23/06	28265	***** 250.00

TWO HUNDRED FIFTY AND 00/100 DOLLARS

Honorable Commissioner of Patents and Trademarks

BELL, BOYD & LLOYD LLC
PATENTS & TRADEMARKS ACCOUNT
NON-NEGOTIABLE

AUTHORIZED SIGNATURE

028265 0710005050 5800036328



In re Patent Application of: Campochiaro et al.

OCULAR GENE THERAPY

Docket No. 116566-053

On the date stamped hereon the U.S. Patent & Trademark Office hereby acknowledges the receipt of the following:

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning A Submission Under 35 U.S.C. 371 (duplicate);
2. Copy of Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US);
3. Petition for Extension of Time (duplicate);
4. Declaration and Power of Attorney (4 pages);
5. Computer-readable form of sequence listing;
6. Sequence Listing Certification;
7. Paper copy of Sequence Listing (8 pages);
8. Check in the amount of \$250.00.

Mailed by First Class Mail by DHN on 23 March 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER
116566-002

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
10/526,127

INTERNATIONAL APPLICATION NO. PCT/EP2003/009497	INTERNATIONAL FILING DATE 27 August 2003	PRIORITY DATE 28 August 2002
---	--	--

**TITLE OF INVENTION
OCULAR GENE THERAPY**

**APPLICANT(S) FOR DO/EO/US
Campochiaro et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
 - a. Is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C.
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11 to 20 below concern document(s) or information

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A preliminary amendment.
14. An application Data Sheet under 37 CFR 1.76.
15. A substitute specification.
16. A power of attorney and/or change of address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/526,127		INTERNATIONAL APPLICATION NO. PCT/EP2003/009497		ATTORNEY'S DOCKET NUMBER 116566-002	
<p>20. <input checked="" type="checkbox"/> Other items or information: Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office; Petition for Extension of Time; Sequence Listing Certification; Sequence Listing; Return Receipt Postcard</p>					
<p>The following fees are submitted:</p> <p>21. <input type="checkbox"/> Basic national fee (37 CFR 1.492(a)) \$300</p> <p>22. <input type="checkbox"/> Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article All other situations.</p> <p>23. <input type="checkbox"/> Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB. All other situations.</p>				CALCULATIONS	PTO USE ONLY
				\$	\$0.00
				\$	\$0.00
				\$	\$0.00
TOTAL OF 21, 22 and 23 =				\$	\$0.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
- 100 =	0 /50 =	0	x	\$250.00	\$ 0.00
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				\$	\$130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =	0	x	\$50.00	\$ 0.00
Independent	- 3 =	0	x	\$200.00	\$ 0.00
Multiple Dependent Claims (if applicable) <input type="checkbox"/>			+ \$360.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	\$130.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.				\$	\$0.00
SUBTOTAL =				\$	\$130.00
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				+	\$
TOTAL NATIONAL FEE =				\$	\$130.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per				+	\$
TOTAL FEES ENCLOSED =				\$	\$130.00
				Amount to be refunded:	\$
				Amount to be charged:	\$


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

- a. A check in the amount of \$130.00 to cover the above fees is enclosed.
- b. Please charge my Deposit Account _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 02-1818. A duplicate copy of this sheet is enclosed.
- d. Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Dean H. Nakamura
Reg. No. 33,981
Bell, Boyd & Lloyd LLC
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (202) 955-6851



SIGNATURE

Dean H. Nakamura

NAME

33,981

REGISTRATION NUMBER



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/526,127	Peter Anthony campochiaro	116566-002
INTERNATIONAL APPLICATION NO.		
PCT/EP03/09497		
I.A. FILING DATE		PRIORITY DATE
08/27/2003		08/28/2002

Dean H Nakamura
 Bell Boyd & Lloyd
 P O Box 1135
 Chicago, IL 60690-1135

CONFIRMATION NO. 2577
371 FORMALITIES LETTER



OC000000017712854

Date Mailed: 12/23/2005

Date: 2-23-06

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 02/28/2005
- U.S. Basic National Fees filed on 02/28/2005
- Priority Documents filed on 02/28/2005

RECEIVED
 BELL, BOYD & LLOYD
 INTELLECTUAL PROPERTY DOCKET

DEC 30 2005

ATTY D.H.W.
 DOCKET # 116566-002

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$130** for a Large Entity:

- **\$130 Surcharge.**

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and

a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

SHELBY J VIGIL

Telephone: (703) 308-9140 EXT 224

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/526,127	PCT/EP03/09497	116566-002

FORM PCT/DO/EO/905 (371 Formalities Notice)

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)
(Large Entity)

Docket No.
116566-002

In Re Application Of: Campochiaro et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/526,127	28 February 2005	Unassigned	29180	Unassigned	2577

Invention: OCULAR GENE THERAPY

COMMISSIONER FOR PATENTS:

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of December 23, 2005 above-identified application.
Date

The requested extension is as follows (check time period desired):

- One month Two months Three months Four months Five months

from: **February 23, 2006** Date _____ until: **March 23, 2006** Date _____

The fee for the extension of time is \$120 and is to be paid as follows:

- A check in the amount of the fee is enclosed.
 - The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. 02-1818 .
 - If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 02-1818
 - Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Dated: 22 March 2006

**Dean H. Nakamura
Reg. No. 33,981
Bell, Boyd & Lloyd LLC
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (202) 955-6851**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
23 March 2006

Signature of Person Mailing Correspondence

Heather Foster

Typed or Printed Name of Person Mailing Correspondence

CC:

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

OCULAR GENE THERAPY

the specification of which: (check one)

- is attached hereto.
- was filed on 28 February 2005, as United States Application No. or PCT International Application No. 10/526,127 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent Office all information which is known to me to be material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code Section 119 or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Day/Month/Year Filed	Priority Not Claimed
PCT/EP03/09497	WIPO	27 August 2003	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
60/406,470	28 August 2002

I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C.F.R., Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint the practitioners at customer number:

29180

as my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and direct that all correspondence be forwarded to the address associated with customer number:

29180

Docket No. 116566-002

Full name of sole or first inventor Peter Anthony Campochiaro	Date
Sole or first inventor's signature 	3/10/06
Residence Baltimore, Maryland	
Citizenship USA	
Post Office Address 920 West Lake Avenue	
Baltimore, Maryland 21210	

Full name of second inventor Michael Kaleko	Date
Second inventor's signature	
Residence Rockville, Maryland	
Citizenship USA	
Post Office Address 8 Hearthstone Court	
Rockville, Maryland 20854	

Full name of sole or first inventor Peter Anthony Campochiaro	
Sole or first inventor's signature	Date
Residence Baltimore, Maryland	
Citizenship USA	
Post Office Address 920 West Lake Avenue	
Baltimore, Maryland 21210	

Full name of second inventor Michael Kaleko	
Second inventor's signature	Date
Residence Rockville, Maryland	
Citizenship USA	
Post Office Address 8 Hearthstone Court	
Rockville, Maryland 20854	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Campochiaro et al.
Appl. No.: 10/526,127
Filed: 28 February 2005
Title: OCULAR GENE THERAPY
Art Unit: Unassigned
Examiner: Unassigned
Docket No.: 116566-002

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


SEQUENCE LISTING CERTIFICATION

Sir:

Enclosed herewith is a computer readable form of the sequence listing. The sequence listing information recorded in computer readable form is identical to the paper sequence listing filed herewith.

Respectfully submitted,

BELL, BOYD & LLOYD LLC



BY

Dean H. Nakamura
Reg. No. 33,981
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (202) 955-6851

Dated: 22 March 2006

SEQUENCE LISTING

<110> NOVARTIS AG
NOVARTIS PHARMA GMBH

<120> OCULAR GENE THERAPY

<130> 116566-010

<140>

<141>

<150> PCT/EP03/09497

<151> 2003-08-27

<150> 60/406,470

<151> 2002-08-28

<160> 25

<170> PatentIn Ver. 3.3

<210> 1

<211> 183

<212> PRT

<213> Homo sapiens

<400> 1

His Ser His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln
20 25 30

Cys Phe Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala
35 40 45

Phe Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro
100 105 110

Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser
130 135 140

Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn
165 170 175

Ser Phe Met Thr Ala Ser Lys
180

<210> 2
<211> 551
<212> DNA
<213> Homo sapiens

<400> 2
acagccaccg cgacttccag ccgggtctcc acctggttgc gctcaacagc cccctgtcag 60
gcccgcgc gggcatccgc ggggcccact tccagtgc tt ccaggcaggcg cggggccgtgg 120
ggctggcggg cacctccgc gccttcctgt cctcgcgcct gcaggacact tacagcatcg 180
tgccgcgtgc cgaccgcga gccgtgcccc tcgtcaacact caaggacgag ctgctgttcc 240
ccagctggga ggctctgttc tcaggctctg agggtcccgct gaagcccgaa gcacgcatt 300
tctccttga cggcaaggac gtcctgaggc accccacactg gccccagaag agcgtgtggc 360
atggctcgga ccccaacggg cgccaggctga ccgagagcta ctgtgagacg tggccggacgg 420
aggctccctc gcccacgggc caggcctcct cgctgctggg gggcaggctc ctggggcaga 480
gtgccgcgag ctgccatcac gcctacatcg tgctctgcat tgagaacagc ttcatgactg 540
cctccaagta g 551

<210> 3
<211> 207
<212> PRT
<213> Mus musculus

<400> 3
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ala Ala His Thr His Gln Asp Phe Gln Pro Val
20 25 30

Leu His Leu Val Ala Leu Asn Thr Pro Leu Ser Gly Gly Met Arg Gly
35 40 45

Ile Arg Gly Ala Asp Phe Gln Cys Phe Gln Gln Ala Arg Ala Val Gly
50 55 60

Leu Ser Gly Thr Phe Arg Ala Phe Leu Ser Ser Arg Leu Gln Asp Leu
65 70 75 80

Tyr Ser Ile Val Arg Arg Ala Asp Arg Gly Ser Val Pro Ile Val Asn
85 90 95

Leu Lys Asp Glu Val Leu Ser Pro Ser Trp Asp Ser Leu Phe Ser Gly
100 105 110

Ser Gln Gly Gln Leu Gln Pro Gly Ala Arg Ile Phe Ser Phe Asp Gly
115 120 125

Arg Asp Val Leu Arg His Pro Ala Trp Pro Gln Lys Ser Val Trp His

130

135

140

Gly Ser Asp Pro Ser Gly Arg Arg Leu Met Glu Ser Tyr Cys Glu Thr
145 150 155 160

Trp Arg Thr Glu Thr Thr Gly Ala Thr Gly Gln Ala Ser Ser Leu Leu
165 170 175

Ser Gly Arg Leu Leu Glu Gln Lys Ala Ala Ser Cys His Asn Ser Tyr
180 185 190

Ile Val Leu Cys Ile Glu Asn Ser Phe Met Thr Ser Phe Ser Lys
195 200 205

<210> 4

<211> 624

<212> DNA

<213> Mus musculus

<400> 4

atggagacag acacactcct gctatggta ctgctgtct gggttccagg ttccactgg 60
gacgcggccc atactcatca ggactttcaag ccagtgtcc acctgggtggc actgaacacc 120
cccctgtctg gaggcatgcg tggtatccgt ggagcagatt tccagtgttt ccagcaagcc 180
cgagccgtgg ggctgtcggg caccttccgg gctttctgt cctcttaggct gcaggatctc 240
tatagcatcg tgcgccgtgc tgaccggggg tctgtgcccc tcgtcaacct gaaggacgag 300
gtgctatctc ccagctggga ctccctgttt tctggctccc agggtcaagt gcaaccggg 360
gcccgcatact tttctttga cgccagagat gtcctgagac acccagcctg gccgcagaag 420
agcgtatggc acggctcggg ccccagtggg cggaggctga tggagagta ctgtgagaca 480
tggcgaactg aaactactgg ggctacaggt caggcctcct ccctgctgtc aggccaggctc 540
ctgaaacaga aagctggcag ctgccacaac agctacatcg tcctgtgcat tgagaatagc 600
ttcatgacct ctttctccaa atag 624

<210> 5

<211> 8

<212> PRT

<213> Homo sapiens

<400> 5

Ala Pro Gln Gln Glu Ala Leu Ala

1

5

<210> 6

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 6

actggtgacg cggccatac tcatcaggac tttcagcc

<210> 7
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 7
aaggctatc gatctagctg gcagaggcct at 32

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 8
cactgcttac tggcttatcg 20

<210> 9
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 9
ctgatgagta tggccgcgt caccagtgg 29

<210> 10
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 10
aaggctatc gatctagctg gcagaggcct at 32

<210> 11
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 11
gatctctaga ccaccatgca tactcatcag gactt 35

<210> 12
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 12
actggagaaa gaggtttatc tagtacttag 30

<210> 13
<211> 18
<212> PRT
<213> Adenovirus

<400> 13
Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser
1 5 10 15
Ala Ala

<210> 14
<211> 96
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 14
gatctctaga ccaccatgag gtacatgatt ttaggcttgc tcgcccttgc ggcagtctgc 60
agcgcgcccc atactcatac tcatcaggac ttccag 96

<210> 15
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 15
atcgatcata ctcatcagga ctttcagcc 29

<210> 16
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 16
gcggccgcct atttggagaa agaggtcat 29

<210> 17
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 17
ttttttttc agtgtaaaag gtc 23

<210> 18
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 18
cagatgacat cctggccag 19

<210> 19
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 19
ctatacagga aagtatggca gc 22

<210> 20

<211> 118
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 20
gccaagcttc catgaggggcc tggatcttct ttctcctttg cctggccggg agggctctgg 60
cagccccctca gcaagaagcg ctcgctcaca gccaccgcga cttccagccg gtgctcca 118

<210> 21
<211> 123
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 21
ccaggtggag caccggctgg aagtgcgcgt ggctgtgagc gagcgcttct tgctgagggg 60
ctgccagagc cctcccggcc aggcaaagga gaaagaagat ccaggccctc atggaagctt 120
ggc 123

<210> 22
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 22
gcgcatgtcg acagaatatg ggccaaac 28

<210> 23
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 23
gcgcatactgc agagctaattg agctacac 28

<210> 24
<211> 27
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 24

ccggctagct taagggtggc gaccggt

27

<210> 25

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 25

gcttcgaacg cgttagcggcc aaccctc

27